June 2024 in “Journal of Clinical Oncology” This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.
1 citations
,
May 2025 in “BMC Cancer” In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.
67 citations
,
October 2005 in “Annals of Oncology” This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.
7 citations
,
September 2024 in “Journal of Comparative Effectiveness Research” This study reports that health-related quality of life was generally maintained, and sometimes improved, in patients with HR+/HER2- advanced or metastatic breast cancer treated with palbociclib, compared to monotherapy, across various study types.